Mod­er­na CEO brush­es off US sup­port for IP waiv­er, eyes more than $19B in Covid-19 vac­cine sales in 2021

Mod­er­na is de­fin­i­tive­ly more con­cerned with keep­ing pace with Pfiz­er in the race to vac­ci­nate the world against Covid-19 than it is with Wednes­day’s de­ci­sion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER